AUM Biosciences announces closing of $27 million in a “Series A” Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies
Home » AUM Biosciences announces closing of $27 million in a “Series A” Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies
AUM Biosciences announces closing of $27 million in a “Series A” Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies2021-10-122021-10-14http://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.pngRedPepper Mergershttp://redpeppermergers.com/wp-content/uploads/rpm-white-red-1.png200px200px
VIEW ARTICLE If you would like to know more regarding the topic in this blog post, please do not hesitate to contact us.